Neurolymphomatosis - Diagnosis and assessment of treatment response by FDG PET-CT

Hematological Oncology

Volumn 26, Issue 1, 2008, Pages 43-45

  Lin, M ^a   Kilanowska, J ^b   Taper, J ^b   Chu, J ^a  

^a LIVERPOOL HOSPITAL   (Australia)

^b Nepean Cancer Care Centre   (Australia)

Author keywords

FDG; Neurolymphomatosis; NHL; PET; Response

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HISTOPATHOLOGY; HUMAN; LUMBAR PUNCTURE; LYMPHOMATOSIS; NERVE BIOPSY; NEUROLOGIC EXAMINATION; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 41349095732     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.837     Document Type: Article

References (11)

1. Hughes RAC, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J Royal Soc Med 1994; 87: 526-530.
2. van den Bent MJ, de Bruin HG, Bos GMJ, Brutel de la Rivière G, Sillevis Smitt PAE. Negative sural nerve biopsy in neurolymphomatosis. J Neurol 1999; 246: 1159-1163.
3. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med 2006; 47: 1326-1334.
4. Rosso SM, de Bruin HG, Wu KL, van den Bent MJ. Diagnosis of neurolymphomatosis with FDG PET. Neurology 2006; 67: 722-723.
5. Kanter P, Zeidman A, Streifler J, et al. PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. Eur J Haematol 2006; 74: 66-69.
6. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro-Oncol 2003; 5: 104-115.
7. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104: 1066-1074.
8. Pakos EE, Fotopoulos A, Ioannidis JPA. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta analysis. J Nucl Med 2005; 46: 958-963.
9. Kostakoglou L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027.
10. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523.
11. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91: 850-854.